
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc. is positioned for significant growth, with a current total addressable market potentially ranging from 500,000 to 1 million diagnosed patients suffering from Mycobacterium Avium Complex lung disease. The company has reiterated its full-year 2025 global revenue guidance for its first commercial product, ARIKAYCE, estimating revenues between $405 million and $425 million, alongside high expectations for the forthcoming Brensocatib launch, which is anticipated to capture a peak sales opportunity of $8.2 billion in bronchiectasis. Additionally, Insmed’s expanded commercial infrastructure and ongoing pipeline developments, including potential label expansion for ARIKAYCE and promising prospects for its Treprostinil Palmitil Inhalation Powder, contribute to a multi-billion dollar valuation outlook for the company's future pipeline.
Bears say
Insmed Inc faces significant financial challenges highlighted by a substantial net loss of $235.5 million for the fourth quarter of 2024 and $913.8 million for the full year, indicating ongoing operational difficulties. Furthermore, the company encounters various risks, including potential delays in regulatory approvals, safety events affecting drug efficacy, and challenges in successfully commercializing its products, which could hinder revenue generation and impact future profitability. Additionally, with ongoing heavy investments in research and development and selling, general, and administrative expenses, Insmed may struggle to maintain financial stability if its commercial efforts do not achieve anticipated success.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares